vs
Side-by-side financial comparison of Five9, Inc. (FIVN) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
Five9, Inc. is the larger business by last-quarter revenue ($300.3M vs $207.8M, roughly 1.4× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $77.3M).
Five9, Inc. is a leading global provider of cloud-native contact center software and solutions. It serves enterprises of all sizes across retail, healthcare, financial services, and technology sectors, offering omnichannel customer engagement tools, AI-powered automation, workforce management, and analytics to boost customer experience and operational efficiency.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
FIVN vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $300.3M | $207.8M |
| Net Profit | — | $119.2M |
| Gross Margin | 55.4% | — |
| Operating Margin | 6.6% | 52.2% |
| Net Margin | — | 57.4% |
| Revenue YoY | 7.8% | — |
| Net Profit YoY | — | 330.1% |
| EPS (diluted) | $0.22 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $300.3M | — | ||
| Q3 25 | $285.8M | $207.8M | ||
| Q2 25 | $283.3M | — | ||
| Q1 25 | $279.7M | — | ||
| Q4 24 | $278.7M | — | ||
| Q3 24 | $264.2M | $0 | ||
| Q2 24 | $252.1M | $0 | ||
| Q1 24 | $247.0M | $0 |
| Q4 25 | — | — | ||
| Q3 25 | $18.0M | $119.2M | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $576.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-4.5M | $-51.8M | ||
| Q2 24 | $-12.8M | $-52.8M | ||
| Q1 24 | $-7.1M | $-39.6M |
| Q4 25 | 55.4% | — | ||
| Q3 25 | 55.0% | — | ||
| Q2 25 | 54.9% | — | ||
| Q1 25 | 55.0% | — | ||
| Q4 24 | 56.0% | — | ||
| Q3 24 | 53.8% | — | ||
| Q2 24 | 53.0% | — | ||
| Q1 24 | 53.6% | — |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.6% | 52.2% | ||
| Q2 25 | -0.6% | — | ||
| Q1 25 | -1.9% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | -7.7% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | 6.3% | 57.4% | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.7% | — | ||
| Q2 24 | -5.1% | — | ||
| Q1 24 | -2.9% | — |
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.21 | $1.33 | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | $0.01 | — | ||
| Q4 24 | $0.16 | — | ||
| Q3 24 | $-0.06 | $-0.60 | ||
| Q2 24 | $-0.17 | $-0.68 | ||
| Q1 24 | $-0.10 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $232.1M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $785.8M | $1.1B |
| Total Assets | $1.8B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $232.1M | — | ||
| Q3 25 | $193.4M | $786.9M | ||
| Q2 25 | $205.5M | — | ||
| Q1 25 | $370.3M | — | ||
| Q4 24 | $362.5M | — | ||
| Q3 24 | $291.0M | $920.0M | ||
| Q2 24 | $175.7M | $701.7M | ||
| Q1 24 | $240.2M | $698.8M |
| Q4 25 | $785.8M | — | ||
| Q3 25 | $775.3M | $1.1B | ||
| Q2 25 | $717.4M | — | ||
| Q1 25 | $664.3M | — | ||
| Q4 24 | $622.2M | — | ||
| Q3 24 | $565.6M | $1.2B | ||
| Q2 24 | $525.9M | $931.7M | ||
| Q1 24 | $483.6M | $935.3M |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.0B | $1.2B | ||
| Q2 24 | $1.9B | $973.7M | ||
| Q1 24 | $1.9B | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.6M | $142.2M |
| Free Cash FlowOCF − Capex | $77.3M | $142.2M |
| FCF MarginFCF / Revenue | 25.8% | 68.4% |
| Capex IntensityCapex / Revenue | 2.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $201.2M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.6M | — | ||
| Q3 25 | $59.2M | $142.2M | ||
| Q2 25 | $35.1M | — | ||
| Q1 25 | $48.4M | — | ||
| Q4 24 | $49.8M | — | ||
| Q3 24 | $41.1M | $-49.2M | ||
| Q2 24 | $19.9M | $-32.9M | ||
| Q1 24 | $32.4M | $-43.8M |
| Q4 25 | $77.3M | — | ||
| Q3 25 | $48.7M | $142.2M | ||
| Q2 25 | $31.6M | — | ||
| Q1 25 | $43.7M | — | ||
| Q4 24 | $40.5M | — | ||
| Q3 24 | $26.7M | $-49.7M | ||
| Q2 24 | $13.1M | $-33.9M | ||
| Q1 24 | $20.4M | $-45.1M |
| Q4 25 | 25.8% | — | ||
| Q3 25 | 17.0% | 68.4% | ||
| Q2 25 | 11.1% | — | ||
| Q1 25 | 15.6% | — | ||
| Q4 24 | 14.5% | — | ||
| Q3 24 | 10.1% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 3.7% | 0.0% | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 4.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.29× | 1.19× | ||
| Q2 25 | 30.38× | — | ||
| Q1 25 | 84.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
